Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $53.88M | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | $849.00K | N/A | N/A | $194.00K | N/A | $10.00K | $30.00K |
| Gross Profit | $53.88M | $-849.00K | N/A | N/A | $-194.00K | N/A | $-10.00K | $-30.00K |
| Gross Margin | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Expenses | $247.08M | $164.96M | $139.87M | $131.26M | $91.70M | $67.48M | $62.87M | $36.05M |
| Operating Income | $-193.19M | $-165.80M | $-139.87M | $-131.26M | $-91.90M | $-67.48M | $-62.88M | $-36.08M |
| Operating Margin | -358.55% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income | $-173.98M | $-152.63M | $-135.84M | $-130.47M | $-89.63M | $-63.14M | $-60.45M | $-35.43M |
| Net Margin | -322.89% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS (Basic) | $-2.02 | $-2.08 | $-2.03 | $-1.97 | $-1.69 | $-1.51 | $-1.72 | $-1.52 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |